About The EMBO Journal

The EMBO Journal

The EMBO Journal is one of the longest-established broad journals in molecular biology, and its identity is unusually easy to pin down. The JournalsWorld record for this profile lists the online ISSN 1460-2075 and the publisher as Springer Nature, and both details fit the journal's current publishing arrangement: the journal is an EMBO Press title, and EMBO Press chose Springer Nature as its publishing partner with effect from 1 January 2024. The print ISSN, recorded in standard serials listings, is 0261-4189. That pairing of identifiers, together with the journal's distinctive name — EMBO is the European Molecular Biology Organization — distinguishes this title from every other journal in the EMBO Press family, including EMBO Reports, EMBO Molecular Medicine and Molecular Systems Biology, which are separate journals with their own ISSNs, scopes and editorial teams.

Readers who arrive at this profile are usually asking one of three questions. Is this the right journal for a manuscript that makes a broad conceptual claim in molecular, cell or developmental biology? What does its editorial process actually reward, beyond technical soundness? And what changed when the journal moved to full open access and to a new publishing partner in 2024? This profile answers those questions from the journal's own aims and scope statement, the EMBO Press announcement of the Springer Nature partnership, and standard indexing and citation sources, and it flags clearly where a figure could not be verified from an official source during this research.

At a glance

History and place in the EMBO family

The journal was established in 1982, at a point when molecular biology was expanding from a set of techniques into a way of explaining how cells, organisms and systems work. For more than four decades it has published full-length research papers describing original work of general interest in molecular biology and related areas. That breadth was deliberate. Accounts of the EMBO publishing programme describe a conscious decision to keep one broad flagship rather than fragment the field into a long list of narrow discipline titles, because a broad journal introduces readers to concepts and results outside their own specialism. Readers can still see that philosophy in the current aims and scope, which ranges well beyond a single technique or model organism.

The publishing home has changed while the title and its community have not. The journal was published on behalf of the European Molecular Biology Organization by other partners in its earlier decades. EMBO then brought its journals together under its own imprint, EMBO Press, launched in 2013, and the four EMBO Press journals developed a shared publishing culture built around close contact between professional editors and the research community, consultative discussion with authors, and a transparent editorial process in which the reasoning behind decisions is made visible rather than hidden.

The most recent change is the move announced on 30 March 2023. EMBO Press selected Springer Nature as its new publishing partner from 1 January 2024 for The EMBO Journal, EMBO Reports, EMBO Molecular Medicine and Molecular Systems Biology. The announcement linked the move to global reach and to the option for authors to transfer manuscripts between journals in the EMBO Press and Springer Nature portfolios. At the same time EMBO Press confirmed a policy decision with direct consequences for every author: from 2024, all papers in its journals are published with full gold open access, and curated source data are posted with fully reproducible methods. Authors considering this journal today are therefore not choosing between a subscription route and an open access route. They are submitting to a fully open access journal, and they should plan funding, licence and data presentation on that basis from the start.

Aims and scope, in depth

The journal's own statement of purpose is selective in a specific way. It publishes research papers of broad general interest, exceptional conceptual advance and functional insight. Those three phrases do most of the editorial work. Broad general interest means the central finding should matter to readers outside the immediate sub-field that produced it. Exceptional conceptual advance means the paper should change how a problem is understood, not only add another observation to an existing picture. Functional insight means the work should explain how something works — a mechanism, a pathway, a structure, a regulatory relationship — rather than present a purely descriptive catalogue, however large the catalogue may be.

The stated coverage runs from molecular cell biology through developmental biology and physiology to ecology, and the journal says studies are selected without preference for specific experimental approaches or model systems. That openness to approach matters in practice. A structural study, a genetic screen, a live-imaging study, a biochemical reconstitution, a computational model and a field-informed ecological study can all, in principle, belong in the same journal, provided each one delivers the conceptual and functional step the journal asks for. Conversely, technically excellent work that stays inside a narrow specialist conversation, or that reports an incremental extension of a well-established result, is a weaker fit here than in a specialist title, even when the experiments themselves are strong.

The subject areas listed by the journal illustrate the breadth concretely. They include ageing; autophagy; biophysics; cancer; cell adhesion, polarity and the cytoskeleton; the cell cycle; cell death; chromatin, epigenetics and genomics; developmental biology; DNA replication, repair and recombination; ecology; evolution; immunology and host–pathogen interaction; membranes and transport; metabolism; microbiology and virology; the molecular biology of disease; neuroscience; plant biology; post-translational modifications and proteolysis; RNA biology; signal transduction; stem cells; structural biology; systems biology and multiomics; chemical and computational biology; transcription and translation; protein biosynthesis and quality control; and vascular biology. A manuscript does not need to span several of these areas. It does need to speak clearly to the readers the journal gathers across them.

One practical feature of the scope deserves emphasis for authors whose work has already been reviewed elsewhere. The journal states that submissions carrying authoritative referee reports from Review Commons or from other journals are welcome and will be considered, where possible, without additional review. Review Commons is the preprint-linked, journal-independent review platform associated with EMBO Press, and this transfer-friendly stance can shorten the path for a strong manuscript that has already had serious external scrutiny. It is not a guarantee of acceptance, and editors still judge fit, but it changes the calculation for authors holding a well-reviewed manuscript that was declined by another broad journal on priority grounds rather than on scientific grounds.

Article types

The core of the journal is the full-length Article: a complete research story with the evidence needed to support a conceptual claim, presented so that a non-specialist molecular biologist can follow why the question matters and what the experiments establish. Alongside Articles, the journal publishes Methods and Resources. Those categories suit work whose main contribution is a capability — a technique, a dataset, a tool or a resource that other groups will use — provided the resource is validated well enough that its value does not rest on promise alone. Authors of methods work should show benchmarking, controls and realistic use cases, because the journal's functional-insight standard applies here too.

The remaining formats are largely commissioned or editorially shaped. Perspectives and Reviews are authoritative synthesis pieces that reframe a field, reconcile conflicting findings or set out where the evidence is genuinely unsettled. Comments, Opinions and News & Views are shorter pieces that place new results or debates in context for the broad readership. Prospective authors of review-type material should normally discuss a proposal with the editorial office before writing a full text, since these sections are planned as part of an issue's overall balance and duplicate coverage is avoided.

Editorial structure and peer review

The journal is led by an editor-in-chief, listed as Facundo D. Batista of Harvard Medical School, and is handled day to day by professional editors working within EMBO Press. That professional-editor model is a defining feature of the EMBO titles. Editors are close to the research community, attend conferences, read widely across the scope, and make the initial judgement that determines whether a manuscript goes to external referees. Authors should therefore treat the cover letter and the abstract as editorial documents, not formalities: they are where the broad interest and conceptual advance must be made legible to an editor deciding, quickly, whether the paper belongs in this journal's conversation.

EMBO Press is also known across its journals for policies designed to make review more constructive and more visible. These include a transparent editorial process, consultative peer review in which referees can discuss a manuscript with one another, pre-decision consultation with authors, and protection against a competing group publishing closely similar work while a manuscript is under consideration — often described as scooping protection. The practical effect authors report valuing most is dialogue: instead of receiving disconnected reports and a bare decision, authors can learn what the essential concerns are and which additional experiments, if any, would actually change the outcome. That does not make review easy. The bar for conceptual advance remains high, and revision requests at this journal can be demanding. It does mean the process is intended to test the central claim thoroughly rather than accumulate an open-ended list of extra experiments.

Integrity expectations follow publisher and EMBO Press policy: original work, clear attribution, disclosure of competing interests, appropriate credit for data and reagents, and complete, reproducible methods. The 2024 open science commitment adds a specific expectation that curated source data accompany published papers. Authors should prepare underlying data files as part of the manuscript, not as an afterthought at proof stage, and should check image-presentation and data-availability requirements in the current author instructions before submission.

Open access, fees and licensing

Since 2024 every paper in The EMBO Journal is published gold open access, freely readable on publication. An article processing charge applies to accepted papers under this model. The exact current charge is set by the publisher and is confirmed on the journal's Springer Nature pages at the time of acceptance; during this research the precise current figure could not be verified from an official journal page, so no specific amount is stated in this profile, and authors should check the live journal site and their own eligibility before budgeting. That caution matters because many authors will not pay the list price personally. Springer Nature operates open access agreements with institutions and funders in many countries, and the EMBO partnership announcement explicitly presented equitable open access as a shared goal. The correct sequence is: check whether your institution has an agreement covering EMBO Press titles, check your funder's open access conditions, and only then treat any remaining charge as a cost to your grant.

Licence terms follow the journal's current open access policy and should be read on the publisher's site at acceptance, particularly for authors with funder mandates that specify a particular Creative Commons licence, and for papers containing material owned by third parties. Authors retain important rights under Springer Nature policy, but reuse of figures from other publications still requires permission where the original licence demands it.

Indexing and metrics

The journal's long history gives it a deep indexing footprint. Standard listings record it as abstracted and indexed in services including Scopus, the Science Citation Index Expanded within Web of Science, MEDLINE and PubMed, Embase, BIOSIS Previews and Biological Abstracts, Chemical Abstracts Service, CAB Abstracts, Aquatic Sciences and Fisheries Abstracts, Current Contents in the life sciences, and EBSCO databases. For authors, the practical points are discoverability in PubMed for biomedical audiences, Scopus and Web of Science coverage for citation tracking and institutional evaluation, and the stability that comes from uninterrupted coverage over decades rather than a recent, provisional listing.

On citation metrics, this profile reports one headline figure with its year attached: a 2024 Journal Impact Factor of 8.2, as reported from Clarivate's Journal Citation Reports. Two cautions belong beside it. First, an impact factor is a journal-level average for a defined citation window; it says nothing reliable about the future citations of an individual paper, and editors at this journal select for conceptual advance rather than predicted citation fashion. Second, figures quoted by third-party aggregator sites for this journal vary widely, including Scopus-based scores presented as if they were the Journal Impact Factor. Authors who need a metric for a formal purpose — a promotion case, a funder report, an institutional evaluation — should take the current figure directly from Journal Citation Reports or from Scopus and SCImago for their respective indicators, with the reporting year stated, rather than copying a number from a summary website.

The JournalsWorld record for this post, at the time of this profile, carried no verified quartile, impact factor, h-index or SJR value of its own, which is why the figures above are attributed to their sources and years instead of being presented as directory data. The journal's standing does not depend on any single indicator: four decades of continuous publication, a flagship position within EMBO Press, and selection for broad conceptual work are the substantive facts, and the metrics follow from them.

How submission works

Submission is made through the journal's online system, reached from its Springer Nature journal home. A complete submission normally comprises the manuscript with figures and legends, a cover letter that states the central finding and its broad significance in plain terms, declarations on competing interests and prior dissemination, and the supporting and source-data files the journal's instructions require. Authors whose manuscripts arrive with reports from Review Commons or another journal should say so clearly and supply those reports and their previous cover correspondence, since the journal explicitly welcomes such submissions for consideration without additional review where possible.

After submission, the editorial office checks scope, completeness and policy compliance, and an editor makes the initial assessment. Manuscripts that do not meet the broad-interest and conceptual-advance threshold are normally returned at this stage — a fast desk decision that authors should read as a fit judgement, not necessarily a quality judgement. Manuscripts sent out are reviewed by external experts, with the consultative and transparent elements described above. Decisions after review range from acceptance subject to revision, through requests for substantial additional work, to rejection with or without encouragement to resubmit a substantially developed study. Transfers within the EMBO Press family, and between EMBO Press and the wider Springer Nature portfolio, are a real option the publisher highlights; a manuscript declined here on priority grounds may be offered a path to a sister journal with its reviews attached, which can save months.

Timelines are not stated as a guaranteed figure in the official material consulted for this profile, so none is quoted here. What authors can control is completeness: a manuscript that arrives with source data prepared, methods written to a reproducible standard, and a cover letter that answers the fit question directly will move faster through every stage than one that has to be returned for missing elements.

Who should — and should not — submit

Submit here when your study makes a mechanistic or conceptual claim that researchers in neighbouring areas of molecular and cell biology will want to rethink their own work around; when the evidence is complete enough that the claim does not depend on a single fragile experiment; and when you can explain, in a paragraph, why the result matters beyond the system in which you found it. The journal's scope list is wide, but its selection standard, not its topic list, is the real gate.

Think carefully before submitting when the work is a solid but specialist advance whose natural readers are concentrated in one narrow community, when the dataset is primarily descriptive without a functional test, or when the same conclusions have already been established in a closely related system and the new paper extends rather than changes them. Those papers often fare better, and are reviewed more happily, in a strong specialist journal. Likewise, clinical studies without a molecular or mechanistic core sit outside the centre of this journal's scope, however important they are clinically.

Strengths, limitations and verification notes

The strengths are reputation, readership breadth, a professional editorial office embedded in its research community, a transparent and consultative review culture, full open access since 2024, and deep, long-standing indexing. The limitations are the mirror image of the strengths: selectivity is high, desk rejection is common for fit reasons, revision can require substantial new experimentation, and full open access brings a publication charge that authors must arrange funding for. None of those limitations is hidden; they are the operating model of a flagship broad journal.

Two identity notes close this profile. First, the JournalsWorld record's publisher field names Springer Nature, which is correct as the current publishing partner, while the journal's owner and imprint remain EMBO Press — both facts are given above so the record is not misread as a Springer Nature-owned title. Second, readers should not confuse this journal with EMBO Reports or EMBO Molecular Medicine when citing metrics or submission links; each EMBO Press title has its own ISSN and editorial criteria, and the 8.2 figure quoted here belongs to The EMBO Journal for 2024.

Frequently asked questions

Is The EMBO Journal open access? Yes. EMBO Press announced that all papers in its journals are published with full gold open access from 2024, and Springer Nature publishes the journal under that model.

What are its ISSNs? Online ISSN 1460-2075, which is the identifier on the JournalsWorld record, and print ISSN 0261-4189.

Can I submit a manuscript already reviewed elsewhere? The journal welcomes submissions with authoritative referee reports from Review Commons or other journals and will consider them, where possible, without additional review. Acceptance is still an editorial decision.

What impact factor should I quote? The 2024 Journal Impact Factor of 8.2, with the year and Journal Citation Reports as the source. Check for a newer release before using the figure formally.

How much is the article processing charge? A charge applies under the gold open access model. The current amount could not be verified from an official journal page during this research, so confirm the live figure, and your eligibility under an institutional agreement, on the journal's Springer Nature pages before submission.

Profile researched from the journal's aims and scope on Springer Nature, the EMBO Press and Springer Nature partnership announcements of March 2023, and standard indexing and citation listings. Facts that could not be verified from official sources are identified as such in the text rather than estimated.